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Objective: Currently investigated non-pharmacological  minimally invasive method for the
treatment of resistant hypertension is percutaneous denervation of renal sympathetic nerve
ﬁbres by radiofrequency catheter-based ablation. We assessed its inﬂuence on renal func-
tion and renal arteries.
Methods: The ﬁrst 38 patients treated with catheter-based renal denervation at our centre
between September 2011 and December 2012 were included in the study. Changes in renal
function and changes in renal artery morphology at 12 months after the procedure have
been analyzed.
Results: Mean age was 57.6  11 years, the majority (63.9%) were men. Average estimated
glomerular ﬁltration rates (eGF) were 1.25 ml/s/1,73 m before2  denervation and 1.30 ml/s /1
1.73 m2 12 months after intervention. Changes in eGF did not reach statistical signiﬁcance.
New haemodynamically non-signiﬁcant renal artery stenosis (40%) has occurred in only one
case after procedure.
Conclusion: In agreement with the results of several studies, our ﬁndings suggest that renal
denervation (RDN) appears to be a safe therapeutic approach.
# 2015 The Czech Society of Cardiology. Published by Elsevier Sp. z o.o. All rights
reserved.
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.Introduction
Arterial hypertension is the most frequent cardiovascular
disease [1]. Approximately 1 billion people worldwide suffer
from hypertension, and it is projected that this number will
increase to 1.5 billion by 2025 [2]. Its prevalence is expected to
increase especially in developing countries [3]. Despite several
available antihypertensive drugs and their unquestionable* Corresponding author . Tel.: +420 724003 901.    
E-mail address: jana.kypusova@npo.agel.cz  (J. Kypusová).
http://dx.doi.org/10.1016/j.crvasa.2015.05.014
0010-8650/# 2015 The Czech Society of Cardiology. Published by Elsebeneﬁcial effects, hypertension control is still unsatisfactory
[4,24]. This fact is attributed to a number of factors such as
inappropriate blood pressure measurement, physician inertia,
excessive salt intake or secondary causes of hypertension.
Apart from the white coat syndrome, patient non-compliance
to a pharmacological therapy is a very frequent phenomenon
[5]. If these factors are excluded and uncontrolled hyperten-
sion persists despite the use of at least 3 antihypertensive
drugs of different classes at maximally tolerated dosesvier Sp. z o.o. All rights reserved.. 
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true prevalence of resistant hypertension remains unknown
because of the absence of a speciﬁcally designed large
prospective study with forced titration. Analyses of clinical
trials suggest a prevalence to range from 10% to almost 30% of
general hypertensive patients in different studies [6,7].
Accumulated evidence indicates that human sympathetic
nervous system deregulation contributes to the development
of arterial hypertension [8,9]. Sympathetic overactivity has
been demonstrated in both essential and secondary forms of
hypertension patients, such as obesity-related hypertension,
end-stage renal disease hypertension and in obstructive sleep
apnea [10].
Over the last few decades, growing knowledge about the
role of the chronic sympathetic overactivity in hypertension
pathophysiology has resulted in the development of an
innovative non-pharmacological therapy that modulates sym-
pathetic activation – percutaneous renal sympathetic dener-
vation. It is an endovascular procedure that uses
radiofrequency energy to destroy the perirenal sympathetic
nerve ﬁbres. RDN decreases both efferent and afferent renal
sympathetic nerve activity. Anatomical regrowth of afferent
renal nerves has not been shown and efferent renal nerves
might be able to regrow to some extent [11]. Primary end point
in the renal artery ablation sympathectomy is to reduce
production of catecholamines, especially noradrenaline. The
renin-angiotensin-aldosteron system is inﬂuenced simulta-
neously. After bilateral renal sympathectomy, the noradrena-
line content in the kidney is reduced by 47% [12]. Renal
perfusion is improved simultaneously [13]. Catheter-based
sympathectomy does not affect negatively other organ
systems and does not cause postural hypotension. It has a
beneﬁcial effect on myocardial remodelling and other vascular
changes associated with severe hypertension and sympathetic
overactivity [14].
Brandt and colleagues [15] demonstrated that RDN in
resistant hypertension patients was associated with a regres-
sion of left ventricle hypertrophy and an improvement of the
diastolic function at 6-months follow-up visit, compared with
the control group. RDN may also inﬂuence other diseases
associated with sympathetic hyperactivity like chronic heart
failure, diabetes mellitus or sleep apnea syndrome [16].
Based on the available evidence from clinical studies,
catheter-based renal denervation has a favourable short-term
safety proﬁle. During follow-up of patients from the multicen-
ter, observational Symplicity HTN-1 trial [17] and from the
randomized controlled Symplicity HTN-2 trial [18], no statisti-
cally signiﬁcant changes in renal function and no vascular
complications such as signiﬁcant stenoses of treated renal
arteries were seen.
The longest available follow-up was at 2 years in the
Symplicity HTN-1 trial [19] with enlarged cohort of 153 patients
at 19 centres in Australia, Europe and USA, in which renal
function remained unchanged during the ﬁrst year of follow-
up. Estimated glomerular ﬁltration rate data of 2 years after the
intervention were only available for 10 patients, in which there
was a mean reduction in eGF of 16 ml/min1/1.73 m2. Five of
these 10 patients had spironolactone or other diuretic added
to the antihypertensive treatment after the ﬁrst year of
follow-up. In the remaining patients without newly addedspironolactone or other diuretic to the treatment, there was a
reduction in estimated glomerular ﬁltration rate (7.8 ml/
min1/1.73 m2). No patient showed doubling of serum
creatinine, development of chronic kidney disease stage IV
or the requirement for dialysis.
Adverse effects of renal denervation on glomerular ﬁltra-
tion rate or renal artery structure was not shown during 6
months of follow-up in the study of Mahfoud and colleagues
[20].
Worthley and colleagues [2] studied the safety of renal
artery denervation in 46 patients at 4 centres in Australia and
Greece using the EnlighHTN catheter (multi-electrode system).
The follow-up interval was 6 months. No acute or late serious
vascular complications occurred and small, non-clinically
relevant changes in average estimated glomerular ﬁltration
rate were reported (87  19 ml/min1/1.73 m2 before RDN
compared with 82  20 ml/min1/1.73 m2 6 months after
RDN).
Gosain and colleagues [21] analyzed 19 studies investigat-
ing the effect of renal denervation on renal function and renal
haemodynamics. They did not ﬁnd a signiﬁcant worsening of
renal function, changes in renal artery anatomy or develop-
ment of clinically signiﬁcant stenosis.
The safety of renal sympathetic denervation has also been
conﬁrmed in a recently published multicentre, prospective,
blinded, randomized and controlled Symplicity HTN-3 trial
[22]. Only one new renal artery stenosis of more than 70% was
veriﬁed at 6-month follow-up period.
Methods
Our aim was to analyze the safety of renal sympathetic
denervation based on the changes in renal function and
changes in renal artery morphology from baseline to 12
months.
A total of 39 patients underwent catheter-based renal
denervation treatment at our centre from 1.9.2011 to
17.12.2012 with subsequent follow-up to 1 year. One patient
was excluded from the study due to absence of 1-year follow-
up visit. A total 38 patients were included in the analysis. All
the patients were conﬁrmed the diagnosis of resistant
hypertension and met all indication criteria of renal denerva-
tion. Patients underwent procedure with the use of radio-
frequency energy delivered by the Medtronic Ardian
SymplicityTM Renal Denervation System. The procedure was
done in the catheterization laboratory in local anaesthesia by
interventional cardiologist and arythmologist. Unfractionated
heparin was administered with activated clotting time (ACT)
monitoring. ECG and vital signs were monitored during the
procedure. The intervention was performed via femoral
access. A 6 French guiding catheter sheath was inserted to
femoral artery, aortography with non-selective renal angiog-
raphy using the pigtail catheter was performed subsequently.
The lumen of the main renal artery was catheterized using
RDND1 catheter (Medtronic, Denver, USA). After renal artery
engagement and completion of a renal angiogram, the
Symplicity ablation catheter was inserted to the renal artery
minimally 5 mm from the main renal artery bifurcation and at
the site where renal artery was minimally 4 mm in diameter.
Table 2 – Medication data.
Antihypertensive agent Number of
patients (%)
Angiotensin-converting enzyme inhibitor 26 (68.42%)
Angiotensin II receptor blocker 19 (50.00%)
Calcium channel blocker 29 (76.32%)
Diuretic 36 (94.74%)
Aldosterone antagonist 13 (34.21%)
Centrally acting sympatholytic agent 21 (55.26%)
Direct-acting renin inhibitor 5 (13.16%)
b-blocker 29 (76.32%)
a-blocker 17 (44.74%)
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applied, and then the ablation catheter was pulled back and
rotated. Further point of ablation was distant from previous by
minimally 5 mm and rotated 908. This continued until
radiofrequency energy was sequentially applied in several
points to the renal artery ostium. The aim was a minimum of
four ablation sites in each main renal artery. The ablation
procedure was then repeated at the contralateral renal artery.
In our analysis, 13.8% of patients did not receive four ablations
on bilateral renal arteries. Procedural data were recorded for
each patient, including blood pressure and heart rate before
and at the end of the intervention, procedure time, volume of
contrast used and number of ablations delivered in each renal
artery.
Renal function was assessed by repeated measurements of
serum creatinine concentration and estimated glomerular
ﬁltration rate using the MDRD (Modiﬁcation of Diet in Renal
Disease) formula. Normality of data was veriﬁed with use of
box plots and Shapiro–Wilk test. The difference between eGF
before RDN and eGF 12 months after the procedure was
analyzed using paired t–test. A 2-tailed p value of <0.05 was
regarded as statistically signiﬁcant.
Renal artery evaluation was conducted in all patients by
computed tomographic angiography at 6 months with the
exception of one patient, in whom magnetic resonance
angiography was done because of radiation protection.
Patient characteristics
Baseline demographic, clinical condition, and medication data
for the 38 patients are shown in Tables 1 and 2. Three patients
did not take a diuretic. They were all documented as ‘‘diuretic
intolerant’’ in the past. However, diagnosis of resistant
hypertension was conﬁrmed by testing the patient's blood
to check for levels of medications they were taking and
secondary causes of hypertension were excluded in a
specialized ofﬁce for resistant hypertension. From all the
patients who were screened for eligibility for RDN, only 7%
were indicated to denervation procedure. In total, 10 patients
(26,32%) received both an angiotensin-converting enzyme
inhibitor (ACEI) and angiotensin II receptor blocker. In previous
guidelines, at a time when the patients underwent the renal
denervation procedure, the use of combination of twoTable 1 – Baseline characteristics.
Mean age at baseline (years  SD) 57.6  11
Gender (female) (%) 36.1
MI  SD (kg/m2) 31.7  4.5
Average eGF before RDN (ml/s1/1.73 m2) 1.25
Average number of antihypertensive drugs  SD 5.5  1.9
Dyslipidaemia (% patients) 68.4
Type 2 diabetes mellitus (% patients) 47.4
CAD (% patients) 31.6
Chronic kidney disease (% patients) 7.9
OSAS (% patients) 5.3
OSAS – obstructive sleep apnoea syndrome; BMI – body mass
index; SD – standard deviation; CAD – coronary artery disease; eGF
– estimated glomerular ﬁltration rate; RDN – renal denervation.different blockers of the RAS (renin-angiotensin system) was
allowed. In two patients with type 2 diabetes mellitus, the
above-mentioned combination of antihypertensive agents
was indicated because of proteinuria.
Results
Unilateral renal artery denervation was performed in 2
patients for anatomical reasons. The remaining 36 patients
underwent bilateral denervation procedure. The mean proce-
dure time was 84 min and the mean number of circumferential
ablations delivered was 5.6 for the right and 5.1 for the left
renal arteries. The mean contrast volume used was 227.3 ml.
In the Symplicity HTN-3 trial the mean volume of contrast
used was 177 ml, while it was 227.3 ml in our patient cohort.
The explanation offered for slightly higher use of contrast is
the maximized effort to adequately performing the procedure
which is crucial for interruption of the renal sympathetic
nerves and sustained blood pressure reduction. Good apposi-
tion between the ablation catheter and target ablation sites in
the renal artery in anterior and posterior position have been
achieved by using the biplane X-ray system (Philips, Integris
Allura FD 20/10).
Patients were scheduled for the follow-up visits at 1-, 3-, 6-
and 12-month after intervention. Average estimated glomer-
ular ﬁltration rate before denervation was 1.25 ml/s1/1.73 m2
and 12 months after intervention 1.30 ml/s1/1.73 m2. Using
the level of statistical signiﬁcance 5%, we found that changes
in average eGF were not statistically signiﬁcant (t = 1.5052;
df = 37; p value = 0.1413) (Fig. 1).
During the follow-up period, we did not show a substantial
deterioration of eGF 1 year after renal artery denervation as
compared with eGF before renal denervation treatment in a
given patient. Only 2 patients reported decrease in eGF of >20%
(decrease by 24% in one patient and decrease by 27% in the
second of them) (Fig. 2). They were females. Both patients had
a history of cancer (breast cancer and carcinoma of the
common bile duct), one patient had a type 2 diabetes mellitus.
Renal functions were normal before denervation treatment. In
these two patients we observed no signiﬁcant differences in
mean volume of contrast used, number of ablations and
procedure time as compared with the other patients. Regard-
ing antihypertensive medications, in one patient the dose of
spironolactone was increased at 6 months after the procedure,
in the second patient no postprocedural changes in antihy-
pertensive medication were reported.
Fig. 1 – Graphic display of mean eGF before RDN and 1 year
after RDN.
Fig. 3 – Protracted renal artery spasm at the site of
radiofrequency energy application making about 70%
reduction in vessel lumen diameter.
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creatinine, development of chronic kidney disease class IV
or required dialysis.
No serious peri-procedural vascular complications oc-
curred with the exception of one patient, in whom protracted
renal artery spasm at the site of radiofrequency energy
application making about 70% reduction in vessel lumen
diameter has been reported (Fig. 3).
In all patients renal artery imaging was completed to
evaluate signs of renal artery irregularities at the 6-month
follow-up visit. This was assessed by computed tomographicFig. 2 – Graphic display of changes in eGF for each ofangiography with the exception of one patient. No evidence of
haemodynamically signiﬁcant renal artery stenoses or other
new structural abnormalities of treated renal arteries was
noted. One patient with peri-procedural renal artery spasm as
mentioned above had a 6-month postprocedure magnetic
resonance angiography because of radiation protection (the
patient had a carcinoma of the common bile duct and regular
abdominal computed tomographic scans to detect the cancer's
stage were being performed). Haemodynamically non-signiﬁ-
cant renal artery stenosis at the site of initial spasm (about of
40% reduction in vessel lumen diameter) was identiﬁed. Six
months later we did renal angiogram for this patient. There
was no progression of renal artery stenosis (about 38%
reduction in vessel lumen diameter) (Figs. 4 and 5). the patients enrolled at baseline and 12 months.
Fig. 4 – Magnetic resonance angiogram 6 months after RDN:
about 40% reduction in vessel lumen diameter at the site of
initial renal artery spasm.
Fig. 5 – Renal angiogram 12 months after RDN: without
progression of stenosis (about 38% reduction in vessel
lumen diameter).
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Over the next few decades, incidence of resistant hypertension
will likely increase given that it is strongly associated with
older age and obesity [23]. Resistant hypertension patients
have an increased cardiovascular risk [24,25]. Thus, in an effort
to minimize hypertension target organ damage, early complex
therapeutic intervention is important.
This study presents data from almost all patients remain-
ing enrolled and followed through 12 months (no deaths, exits
for any reason or lost to follow-up). Only one visit was missed
due to the hospitalization for ischaemic stroke recurrence. The
stroke occurred 11 months after renal denervation. Therefore
we are assuming it had no relationship to the ablation
procedure. We contacted the ward, where the patient was
hospitalized regarding blood pressure values and antihyper-
tensive treatment.
The safety of RDN seen in our study is comparable with
results published in several other renal-denervation studies
[2,17,19,21,26]. The safety of RDN has been proven in studies
using the single electrode radiofrequency catheter system
[17,19,22,26], as well as in study using the multi-electrode
radiofrequency system [2].
With regard to published data on worsening renal function
2 years after denervation procedure, consistent follow-up ofrenal function, especially for a longer-term period is required.
It is interesting to speculate as to why renal functions
worsened in two patients in our study. Procedure time and
contrast volume were not signiﬁcantly different from the
other patients. A reduction in glomerular ﬁltration rate in one
patient may have bee due to increased dose of spironolactone.
Deterioration of renal function in the second patient is
unclear.
Concerning vascular complications, the available evidence
from clinical studies reveals that catheter-based renal dener-
vation has an excellent short-term safety proﬁle. Inspite of
small probability, a risk of renal artery stenosis during long-
term follow-up cannot be excluded.
Our analysis has some limitations. First limitation is
relative small sample size and we only focused on safety.
Another limitation which need to be considered in the
interpretation of these results is the fact that follow-up of
renal function and renal arteries anatomy for a longer period
of time is necessary.
Conclusions
Denervation of renal sympathetic nerves using a single
electrode ablation catheter Symplicity was performed without
compromising patient safety. Twelve months after the
intervention there was no statistically signiﬁcant decrease
in eGF. Only 2 patients reported decrease in eGF of >20%. No
patient experienced a twofold increase in serum creatinine,
development of chronic kidney disease class IV or required
dialysis.
No serious vascular events associated with renal dener-
vation procedure occurred. In one patient, protracted
renal artery spasm at the site of radiofrequency energy
application resulting in about 70% reduction in vessel
lumen diameter has been reported. Six months after the
procedure, haemodynamically non-signiﬁcant renal artery
stenosis at the site of initial spasm (about of 40% reduction
in vessel lumen diameter) was revealed. Six months later we
did renal angiogram without detecting progression of
stenosis.
Renal denervation is a method which is still in the
advanced phase of clinical research. Further analyses and
subgroup analyses are mandatory to investigate deﬁnitive
appraisal of this therapeutic strategy in the management of
resistant hypertension. Especially randomized trials investi-
gating the efﬁcacy and safety of catheter-based renal
denervation during longer observation periods are necessary
to detect changes in renal function and development of late
renal artery stenoses.
The challenge is a selection of eligible patients and their
subsequent follow-up, as well as how to assess the treatment
effect of the renal denervation procedure (blood pressure
decrease is not immediate, but occurs during the next days
after procedure).
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